Indeed, TCGA analyses showed increased expression of several MAPK TFs in mesothelioma, specifically the ones belonging to the ELK, ELF and AP-1 subfamilies (Fig. S9G) and we observed synergistic anti-proliferative effects with combined treatment of a TEAD inhibitor and several agents inhibiting MAPK pathway at different levels (Fig. 5c). Here, JUN is linked to mesothelioma.